

Giulia Rovesti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3718029/giulia-rovesti-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21
papers

238
citations

8
h-index

15
g-index

23
ext. papers

350
ext. citations

4.7
avg, IF

3
L-index

#	Paper	IF	Citations
21	TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. <i>American Journal of Cancer Research</i> , 2021 , 11, 4500-4514	4.4	
20	Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board. <i>Nutrients</i> , 2021 , 13,	6.7	3
19	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. <i>Tumori</i> , 2021 , 107, 550-555	1.7	2
18	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	
17	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , 2021 , 23, 915-920	3.8	4
16	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6	2
15	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	6
14	Association of and Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020 , 26, 4485-4493	12.9	9
13	H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. <i>Cancers</i> , 2020 , 12,	6.6	19
12	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020 , 15, 773-785	5	8
11	Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920958363	5.4	5
10	Validation and refinement of PROSASH model using the neutrophil-to-lymphocyte ratio in patients with HCC receiving sorafenib. <i>Liver Cancer International</i> , 2020 , 1, 6-11	0.8	
9	BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives. <i>Cancers</i> , 2020 , 12,	6.6	5
8	First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?. <i>European Journal of Cancer</i> , 2020 , 137, 108-116	7.5	6
7	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. <i>Journal of Hepatology</i> , 2019 , 71, 1175-1183	13.4	35
6	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. <i>Gastrointestinal Tumors</i> , 2019 , 6, 92-107	1.3	19
5	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. <i>Scientific Reports</i> , 2019 , 9, 1788	4.9	36

4	Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. <i>Cancer Gene Therapy</i> , 2019 , 26, 11-16	5.4	28
3	and Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Cancers</i> , 2019 , 11,	6.6	19
2	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , 2019 , 6, 71-80	1.3	4
1	MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. <i>Theranostics</i> , 2019 , 9, 436-448	12.1	25